ImmunityBio Announces Positive ANKTiva Trial Result
ImmunityBio announced a primary efficacy endpoint win in its bladder cancer trial. This regulatory milestone supports a potential 2026 sBLA for the cancer immunotherapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed